aetna®

MEDICARE FORM

Darzalex™ (daratumumab) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
Phone: 1-866-503-0857 (TTY: 711)
FAX: 1-844-268-7263

For other lines of business:
Please use other form

Note: Darzalex is non-preferred. The preferred product is bortezomib.

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	E-mail:	

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:	Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.				
Address:	City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider E-mail:	Office Contact Name:	Phone:			

Specialty *(Check one):* ☐ **Oncologist** ☐ **Hematologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other: _____
Name: _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

E. PRODUCT INFORMATION

Request is for Darzalex (daratumumab):
Dose: _____ **Frequency:** _____ **HCPCS Code:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For Initiation Requests (clinical documentation required for all requests):

Note: Darzalex is non-preferred. The preferred product is bortezomib.

☐ Yes ☐ No Has the patient had prior therapy with Darzalex (daratumumab) within the last 365 days?
☐ Yes ☐ No Will Darzalex be used in combination with bortezomib?
☐ Yes ☐ No Has the patient had a trial and failure, intolerance, or contraindication to bortezomib?
Please explain if there are any other medical reason(s) that the patient cannot use bortezomib when indicated for the patient's diagnosis?

_____

Continued on next page

aetna®

MEDICARE FORM
Darzalex™ (daratumumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
Phone: 1-866-503-0857 (TTY: 711)
FAX: 1-844-268-7263

For other lines of business:
Please use other form

Note: Darzalex is non-preferred. The preferred product is bortezomib.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(Continued)* - Required clinical information must be completed for ALL precertification requests.

For All Requests (clinical documentation required for all requests):

☐ **Multiple myeloma**

What is the prescribed regimen?

☐ Darzalex in combination with bortezomib, melphalan, and prednisone
- → ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?

☐ Darzalex in combination with bortezomib and dexamethasone
- → ☐ Yes ☐ No Has the patient received at least one prior therapy?

☐ Darzalex in combination with lenalidomide and dexamethasone
- → ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?
- ☐ Yes ☐ No Has the patient received one or more prior therapies?

☐ Darzalex in combination with bortezomib, thalidomide, and dexamethasone
- → ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?
- ☐ Yes ☐ No Will the requested medication be used for a maximum of 16 doses?

☐ Darzalex in combination with pomalidomide and dexamethasone
- → ☐ Yes ☐ No Has the patient received at least two prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent?

☐ Darzalex in combination with carfilzomib and dexamethasone
- → ☐ Yes ☐ No Is the patient's disease relapsed or progressive?

☐ Darzalex in combination with cyclophosphamide, bortezomib and dexamethasone

☐ Darzalex in combination with bortezomib, lenalidomide and dexamethasone
- → ☐ Yes ☐ No Is the patient eligible for transplant?
- ☐ Yes ☐ No Will the requested medication be used as primary therapy?

☐ Darzalex as a single agent
- → ☐ Yes ☐ No Has the patient received at least three prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent?
  - → ☐ Yes ☐ No Is the patient double refractory to a PI and an immunomodulatory agent?

☐ Other regimen (please explain): _____

☐ **Systemic light chain amyloidosis**

☐ Yes ☐ No Is the patient's disease relapsed or refractory?

For Continuation Requests: (Clinical documentation required for all requests)

☐ Yes ☐ No Has the patient experienced disease progression or unacceptable toxicity while on current regimen?
- → Please select: ☐ disease progression ☐ unacceptable toxicity

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.